Expired Remdesivir Doses Raise Concerns in Kerala Nipah Treatment
Kerala has been rocked by a fresh controversy over the treatment of Nipah patients. Health Minister K. Muraleedharan has raised doubts about the medicines administered during the previous government's tenure, including whether some patients received drugs intended for clinical trials.
Addressing journalists in Kozhikode on Friday, the minister said some of the supplied medicines did not have a manufacturing date printed on them. He said a broad inquiry had been ordered on the basis of details shared by the Kozhikode Medical College superintendent.
The investigation will look into the foreign pharmaceutical firms involved in the supply chain. It will also examine intermediaries who facilitated the transactions and any financial gains they obtained.
The revelations came a day after the minister told the Assembly on Thursday that Remdesivir, purchased in 2021 with an expiry date of May 30, 2023, had been used in later years.
According to the statement, the Kerala Medical Services Corporation Limited bought 3,000 vials on June 3, 2021, for Rs 42 lakh. Hospital records indicate that 102 vials were used in 2023-24, 34 in 2024-25 and 10 in 2025-26.
The minister added that 50 vials used in 2026 were ordered separately from Bahrain on June 12, 2026.
To determine the impact, a medical board led by Dr. R. Aravind, head of the infectious diseases department at Thiruvananthapuram Medical College, has been formed. The panel will check whether the suspected use of expired drugs was linked to patient deaths and whether other recipients experienced side effects.
Muraleedharan also pushed back against claims in a letter from Opposition Leader Pinarayi Vijayan. He said the letter only warned against giving patients low-cost medicines and did not refer to clinical trial drugs or expired stock.
The government, he said, would act appropriately once the inquiry establishes all the facts. The matter pertains to 2016-26, a period when Pinarayi Vijayan was leading the state.